Overview
Switzerland specialty chemical firm's Q1 sales fell 2% in local currency
Adjusted EBITDA margin before exceptionals dropped to 17.5% from 18.8% a year earlier
Middle East conflict and portfolio pruning weighed on Catalyst and Care Chemicals performance
Outlook
Clariant expects 2026 sales in local currency to be around 2025 levels
Company sees 2026 EBITDA margin before exceptional items at around 18%
Clariant expects 2026 free cash flow conversion of over 40%
Result Drivers
MIDDLE EAST CONFLICT - Co said conflict led to lower Catalyst volumes, pushed out orders, and affected Oil Services in Care Chemicals
PORTFOLIO PRUNING - Portfolio pruning reduced Care Chemicals volumes and sales, contributing to overall group decline
LOWER PRICING - Formula-based price adjustments, reflecting lower raw material costs until the start of the Middle East conflict, weighed on group and segment pricing
Company press release: ID:nGNE7llltX
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Meet
CHF 918 mln
CHF 918 mln (1 Analyst)
Q1 Adjusted EBITDA
Miss
CHF 160.20 mln
CHF 167 mln (1 Analyst)
Q1 EBITDA
CHF 157.80 mln
Q1 EBITDA Margin
17.20%
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 10 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy."
Wall Street's median 12-month price target for Clariant AG is CHF8.00, about 1.2% below its May 7 closing price of CHF8.10
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)